SEOM clinical guidelines for the treatment of malignant pleural mesothelioma (2020)
Gespeichert in:
| Titel: | SEOM clinical guidelines for the treatment of malignant pleural mesothelioma (2020) |
|---|---|
| Autoren: | E. Nadal, J. Bosch-Barrera, S. Cedrés, J. Coves, R. García-Campelo, M. Guirado, R. López-Castro, A. L. Ortega, D. Vicente, J. de Castro-Carpeño |
| Weitere Verfasser: | Institut Català de la Salut, [Nadal E] Department of Medical Oncology, Catalan Institute of Oncology, Hospital Duran i Reynals, Avda Gran Via 199-203, l’Hospitalet de Llobregat, Barcelona, Spain. [Bosch-Barrera J] Department of Medical Oncology, Catalan Institute of Oncology, Hospital Josep Trueta, Girona, Spain. [Cedrés S] Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Servei d’Oncologia Mèdica, Vall d’Hebron Hospital Universitari, Barcelona, Spain. [Coves J] Department of Medical Oncology, Hospital Son Llatzer, Palma de Mallorca, Spain. [García-Campelo R] Department of Medical Oncology, Complejo Hospitalario Universitario A Coruña, Coruña, Spain. [Guirado M] Department of Medical Oncology, Hospital General Universitario de Elche, Elche, Spain, Vall d'Hebron Barcelona Hospital Campus |
| Quelle: | Clin Transl Oncol CLINICAL & TRANSLATIONAL ONCOLOGY r-FISABIO. Repositorio Institucional de Producción Científica instname Docusalut Conselleria de Salut i Consum del Govern de les Illes Balears Scientia Scientia. Dipòsit d'Informació Digital del Departament de Salut RISalud-ANDALUCIA. Repositorio Institucional de Salud de Andalucía Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL)) Dipòsit Digital de la UB Universidad de Barcelona Repositorio Institucional de la Consejería de Sanidad de la Comunidad de Madrid Consejería de Sanidad de la Comunidad de Madrid Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO) |
| Verlagsinformationen: | Springer Science and Business Media LLC, 2021. |
| Publikationsjahr: | 2021 |
| Schlagwörter: | Mesothelioma, Clinical guidelines, DISEASES::Neoplasms::Neoplasms by Histologic Type::Neoplasms, Glandular and Epithelial::Adenoma::Mesothelioma, Pleural Neoplasms, Malignant pleural mesothelioma, Clinical Guides in Oncology, Antineoplastic Agents, Platinum Compounds, Càncer - Quimioteràpia, Pemetrexed, Medical Oncology, Deoxycytidine, 03 medical and health sciences, 0302 clinical medicine, Diagnòstic, Diagnosis, Humans, Diagnostic, Genetic Testing, Societies, Medical, ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Therapeutics::Combined Modality Therapy, Neoplasm Staging, Radiotherapy, Mesothelioma, Malignant, High-Throughput Nucleotide Sequencing, Asbestos, Vinorelbine, Cytoreduction Surgical Procedures, Gemcitabine, Combined Modality Therapy, Medical protocols, 3. Good health, Treatment, Mesotelioma, Spain, Carcinogens, Càncer - Immunoteràpia, Protocols clínics, ENFERMEDADES::neoplasias::neoplasias por tipo histológico::neoplasias glandulares y epiteliales::adenoma::mesotelioma, Immunotherapy, TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::terapéutica::tratamiento combinado |
| Beschreibung: | Mesothelioma is a rare and aggressive tumour with dismal prognosis arising in the pleura and associated with asbestos exposure. Its incidence is on the rise worldwide. In selected patients with early-stage MPM, a maximal surgical cytoreduction in combination with additional antitumour treatment may be considered in selected patients assessed by a multidisciplinary tumor board. In patients with unresectable or advanced MPM, chemotherapy with platinum plus pemetrexed is the standard of care. Currently, no standard salvage therapy has been approved yet, but second-line chemotherapy with vinorelbine or gemcitabine is commonly used. Novel therapeutic approaches based on dual immunotherapy or chemotherapy plus immunotherapy demonstrated promising survival benefit and will probably be incorporated in the future. |
| Publikationsart: | Article Other literature type |
| Dateibeschreibung: | application/pdf |
| Sprache: | English |
| ISSN: | 1699-3055 1699-048X |
| DOI: | 10.1007/s12094-020-02532-2 |
| Zugangs-URL: | https://link.springer.com/content/pdf/10.1007/s12094-020-02532-2.pdf https://pubmed.ncbi.nlm.nih.gov/33538989 https://fundanet.fisabio.san.gva.es/publicaciones/ProdCientif/PublicacionFrw.aspx?id=11773 http://hdl.handle.net/20.500.13003/16111 https://hdl.handle.net/11351/6155 http://hdl.handle.net/10668/17102 https://hdl.handle.net/2445/174668 http://hdl.handle.net/2445/174668 https://hdl.handle.net/20.500.12530/67793 https://fisabio.portalinvestigacion.com/publicaciones/11773 https://link.springer.com/article/10.1007/s12094-020-02532-2 https://dialnet.unirioja.es/servlet/articulo?codigo=7916623 https://www.ncbi.nlm.nih.gov/pubmed/33538989 http://diposit.ub.edu/dspace/handle/2445/174668 https://link.springer.com/content/pdf/10.1007/s12094-020-02532-2.pdf https://pubmed.ncbi.nlm.nih.gov/33538989/ https://hdl.handle.net/20.500.13003/16111 https://hdl.handle.net/10668/17102 |
| Rights: | CC BY URL: http://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (http://creativecommons.org/licenses/by/4.0/) . |
| Dokumentencode: | edsair.doi.dedup.....57be013f2fef4c0aaf8c39391f3ff5ad |
| Datenbank: | OpenAIRE |
Full Text Finder 
Nájsť tento článok vo Web of Science | Abstract: | Mesothelioma is a rare and aggressive tumour with dismal prognosis arising in the pleura and associated with asbestos exposure. Its incidence is on the rise worldwide. In selected patients with early-stage MPM, a maximal surgical cytoreduction in combination with additional antitumour treatment may be considered in selected patients assessed by a multidisciplinary tumor board. In patients with unresectable or advanced MPM, chemotherapy with platinum plus pemetrexed is the standard of care. Currently, no standard salvage therapy has been approved yet, but second-line chemotherapy with vinorelbine or gemcitabine is commonly used. Novel therapeutic approaches based on dual immunotherapy or chemotherapy plus immunotherapy demonstrated promising survival benefit and will probably be incorporated in the future. |
|---|---|
| ISSN: | 16993055 1699048X |
| DOI: | 10.1007/s12094-020-02532-2 |